Professor Jair Bar
Head of the lung cancer department at the medical center, Israel's leading specialist in treating lung cancer and chest tumors.
Professor Jair Bar is one of the most significant figures in clinical oncology in Israel. In conservative treatment of cancer, Dr. Bar achieves the highest results possible for a given diagnosis, so he has thousands of grateful patients who owe their health to his professionalism.
Dr. Jair Bar graduated from the Faculty of Medicine of the Hebrew University in Jerusalem. After graduating he trained at Sheba Medical Center in radiotherapy and chemotherapy, then underwent in-depth specialization in non-surgical treatment of lung cancer and chest tumors at the oncology clinic of a leading medical center in Ottawa (Canada).
Alongside clinical practice, Dr. Bar has conducted and continues to conduct active research in innovations in conservative anticancer treatment, including therapy of chest and mediastinal cancer.
Professor Bar is a physician of the highest category and a brilliant scientist, a member of several Israeli and international professional organizations as an expert in conservative oncology, who takes an active part in research on introducing the latest drugs for lung cancer treatment. Dr. Bar has published dozens of important papers on treating cancer of the lungs, mediastinum and chest in prestigious international scientific medical journals. He received his doctoral degree for research in lung cancer oncology at the Weizmann Institute (Israel).
Today Jair Bar is head of the lung cancer department at the medical center, Israel's leading clinical specialist in treating lung cancer and chest tumors, and head of a scientific and practical laboratory studying molecular cancer processes. His competence includes:
- radiation therapy and chemotherapy for cancer of the chest and mediastinal organs, including the lungs and bronchi;
- targeted cancer therapy aimed at minimizing the risks of anticancer treatment;
- biological therapy of oncological diseases at all stages of tumors and metastasis;
- selection of cancer treatment from modern drugs and their combinations, taking concomitant pathology into account;
- development of individual conservative cancer treatment programs including drugs that reduce side effects of the main therapy.